tetano
Editor, Senior Moderator
Sci Rep
. 2023 Nov 19;13(1):20235.
doi: 10.1038/s41598-023-47690-9. Influenza vaccination and major cardiovascular risk: a systematic review and meta-analysis of clinical trials studies
Fatemeh Omidi[SUP] 1 [/SUP], Moein Zangiabadian[SUP] 2 3 [/SUP], Amir Hashem Shahidi Bonjar[SUP] 4 [/SUP], Mohammad Javad Nasiri[SUP] 5 [/SUP], Tala Sarmastzadeh[SUP] 6 [/SUP]
Affiliations
Cardiovascular events remain a substantial global health concern, necessitating innovative strategies for prevention. This study aims to assess the potential impact of influenza vaccination on major cardiovascular events. A search of the medical English literature was conducted using PubMed/MEDLINE, EMBASE, and the Cochrane CENTRAL up to 1 August 2023. Meta-analysis and stratified analyses were performed to investigate specific outcomes, including myocardial infarction (MI), cardiovascular death, and stroke. Pooled relative risks (RR) along with their 95% confidence intervals (CI) were calculated to evaluate the associations. A comprehensive analysis was conducted on a total of 9059 patients, with 4529 patients receiving the influenza vaccine and 4530 patients receiving a placebo. Among patients who received the influenza vaccine, a notable reduction in the occurrence of major cardiovascular events was observed, with 517 cases compared to 621 cases in the placebo group (RR 0.70; 95% CI 0.55-0.91). The stratified analysis revealed a decreased risk of MI in vaccinated patients (RR 0.74; 95% CI 0.56-0.97) and a significant reduction in cardiovascular death events (RR 0.67; 95% CI 0.45-0.98). This study provides compelling evidence that influenza vaccination is associated with a decreased risk of major cardiovascular events, particularly myocardial infarction, and cardiovascular death. These findings highlight the potential of influenza vaccination as an adjunctive strategy in cardiovascular disease prevention. Further research and exploration of underlying mechanisms are warranted to elucidate the observed beneficial effects.
. 2023 Nov 19;13(1):20235.
doi: 10.1038/s41598-023-47690-9. Influenza vaccination and major cardiovascular risk: a systematic review and meta-analysis of clinical trials studies
Fatemeh Omidi[SUP] 1 [/SUP], Moein Zangiabadian[SUP] 2 3 [/SUP], Amir Hashem Shahidi Bonjar[SUP] 4 [/SUP], Mohammad Javad Nasiri[SUP] 5 [/SUP], Tala Sarmastzadeh[SUP] 6 [/SUP]
Affiliations
- PMID: 37981651
- PMCID: PMC10658159
- DOI: 10.1038/s41598-023-47690-9
Cardiovascular events remain a substantial global health concern, necessitating innovative strategies for prevention. This study aims to assess the potential impact of influenza vaccination on major cardiovascular events. A search of the medical English literature was conducted using PubMed/MEDLINE, EMBASE, and the Cochrane CENTRAL up to 1 August 2023. Meta-analysis and stratified analyses were performed to investigate specific outcomes, including myocardial infarction (MI), cardiovascular death, and stroke. Pooled relative risks (RR) along with their 95% confidence intervals (CI) were calculated to evaluate the associations. A comprehensive analysis was conducted on a total of 9059 patients, with 4529 patients receiving the influenza vaccine and 4530 patients receiving a placebo. Among patients who received the influenza vaccine, a notable reduction in the occurrence of major cardiovascular events was observed, with 517 cases compared to 621 cases in the placebo group (RR 0.70; 95% CI 0.55-0.91). The stratified analysis revealed a decreased risk of MI in vaccinated patients (RR 0.74; 95% CI 0.56-0.97) and a significant reduction in cardiovascular death events (RR 0.67; 95% CI 0.45-0.98). This study provides compelling evidence that influenza vaccination is associated with a decreased risk of major cardiovascular events, particularly myocardial infarction, and cardiovascular death. These findings highlight the potential of influenza vaccination as an adjunctive strategy in cardiovascular disease prevention. Further research and exploration of underlying mechanisms are warranted to elucidate the observed beneficial effects.